Local healthcare accelerator Health Wildcatters added ten new startups to its portfolio in its ninth cohort this fall. There have been 88 total startups in the organization’s umbrella, and the latest cohort includes entrepreneurs with roots in five continents, and half are led by females. Learn more from the release below.
A LaRue Company (Winston-Salem, NC) – Designer of the LaRue Surgical Evacuator and Clean Removal Process to aid surgeons in providing patients a safe, rapid, less invasive procedure for removing gelatinous and similar materials from the body or surgical site.
Aliform (Aachen, Germany) – Developing minimally-invasive surgical devices for treating skin conditions.
AllergenIQ (Southlake, TX)– Digital health telemedicine platform that provides comprehensive integrative care, support, and treatment for children who have allergic conditions including food allergies.
Birkeland Current – SOVRINTI (Waco, TX) – Changing the future of independent aging and home-based care by scaling senior functional assessment to support earlier clinical diagnosis, person-centered home care, and timely care interventions.
Oral Genome (Carlsbad, CA) – Send in your saliva and receive personalized insights about your oral health and recommended preventative measures.
Parrots Inc. (Seattle, WA) – Creator of “Polly”, an inclusive platform using AI and machine learning to give a smart voice and telecare to people with neurological disorders.
RECORNEA (Udine, Italy) – is a pre-clinical stage medtech ophthalmic company developing therapeutic corneal implants.
Lung Healing Technologies, Inc. (Winnetka, IL) – SmartDrain monitors the CO2, O2, and pressure in a chest drain to reduce hospitalization costs by over $4k per patient or $1B per year in the US alone.
Spectryx (Palo Alto, CA) – Transforming the drug development industry with high-throughput, label-free, ultra-sensitive automated sensors.
Sympal (Boston, MA) – Clear aligner company disrupting the orthodontic industry.
Specialty pharmacy services company Soleo Health has launched its Thyroid Eye Disease Therapeutic Care Management Center to care for and treat patients with thyroid eye disease. The rare ophthalmic, vision-threatening condition will be treated with the TEPEZZA, the first and only U.S. Food and Drug Administration-approved treatment for TED.
TechFW client Trémedics received Breakthrough Device designation from the FDA approval for its stent for congenital heart disease developed for infants (30 days) to children up to 14 years. The designation is given to medical devices that have the potential to provide improved treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions.